Table 1 Patient characteristics
Baseline characteristic | 3-weekly (n = 127) | Weekly (n = 187) | Total (n = 314) | p-value |
|---|---|---|---|---|
Centre | < 0,0011 | |||
- USB | 124 (97,6%) | 0 (0%) | 124 (39,5%) | |
- KSW | 3 (2,4%) | 58 (32%) | 61 (19,4%) | |
- USZ | 0 (0%) | 129 (69%) | 129 (41,1%) | |
Age at diagnosis, mean (SD) | 60.4 (8.1) | 59.9 (8.7) | 60.1 (8.5) | 0.5582 |
Gender | 0.2731 | |||
- Male | 102 (80.3%) | 139 (74.3%) | 241 (76.8%) | |
- Female | 25 (19.7%) | 48 (25.7%) | 73 (23.2%) | |
Tumor localisation | 0.1561 | |||
- Oropharynx | 57 (45.2%) | 102 (54.8%) | 159 (51%) | |
- Oral cavity | 30 (23.8%) | 27 (14.5%) | 57 (18.3%) | |
- Hypopharynx | 21 (16.7%) | 27 (14.5%) | 48 (15.4%) | |
- Larynx | 10 (7.9%) | 21 (11.3%) | 31 (9.9%) | |
- CUP | 5 (4.0%) | 8 (4.3%) | 13 (4.2%) | |
- Nasopharynx | 3 (2.4%) | 1 (0.5%) | 4 (1.3%) | |
Smoking History | 0.0871 | |||
- Smoker | 105 (92.9%) | 155(85.6%) | 260 (88.4%) | |
- Non smoker | 8 (7.1%) | 26 (14.4%) | 34 (11.6%) | |
HPV Status | 0.0931 | |||
-Positive | 21 (16.5%) | 34 (18.2%) | 55 (17.5%) | |
- Negative | 32 (25.2%) | 29 (15.5%) | 61 (19.4%) | |
- Unknown | 74 (58.3%) | 124 (66.3%) | 198 (63.1%) | |
T Stage | 0.0811 | |||
- T0 | 0 | 1 (0.6%) | 1 (0.3%) | |
- T1 | 14 (11.7%) | 29 (16.2%) | 43 (14.4%) | |
- T2 | 36 (30.0%) | 74 (41.3%) | 110 (36.8%) | |
- T3 | 31 (25.8%) | 35 (19.6%) | 66 (22.1%) | |
- T4 | 39 (32.5%) | 40 (22.3%) | 79 (26.4%) | |
N Stage | 0.6271 | |||
- N0 | 24 (19.0%) | 43 (23.0%) | 67 (21.4%) | |
- N1 | 13 (10.3%) | 25 (13.4%) | 38 (12.1%) | |
- N2 | 83 (65.9%) | 112 (59.9%) | 195 (62.3%) | |
- N3 | 6 (4.8%) | 7 (3.7%) | 13 (4.2%) | |
M Stage | 0,4823 | |||
- M0 | 115 (90.5%) | 160 (85.5%) | 275 (87.5%) | |
- M1 | 5 (3.9%) | 3 (1.6%) | 8 (2.5%) | |
Advanced Disease (> = T2 & > = N2) | 0,0341 | |||
- Yes | 77 (64,2%) | 99 (51.1%) | 169 (56.3%) | |
- No | 43 (35,8%) | 88 (48,9%) | 131 (43,7%) | |
Type of CRT | 0.1471 | |||
- Definitive | 78 (61.4%) | 126 (67.3%) | 204 (64.9%) | |
- Adjuvant | 49 (38.6%) | 61 (32.7%) | 110 (35.1%) | |